Find Research Projects

Search results

• Antiviral Countermeasure Development Center (AC/DC)

  Freiberg, A.

  Emory University

  1/1/00 → 1/1/00

  Project: Other project

• Antiviral Drug Testing and Resistance Selection

  Shi, P.

  1/1/00 → 1/1/00

  Project: Other project

• Antiviral Drug Testing and Resistance Selection

  Shi, P.

  Atea Pharmaceuticals Incorporated

  1/1/00 → 1/1/00

  Project: Other project

• Antiviral Drug Testing and Resistance Selection

  Shi, P.

  Atea Pharmaceuticals Incorporated

  2/1/21 → 10/31/21

  Project: Other project

• Antiviral Drug Testing and Resistance Selection

  Shi, P.

  2/1/21 → 10/31/21

  Project: Other project

• Antiviral profiling of alphavirus inhibitors

  Weaver, S.

  3/1/15 → 2/15/16

  Project: Other project

• Antiviral profiling of alphavirus inhibitors

  Weaver, S.

  3/1/15 → 2/15/16

  Project: Other project

• Antiviral profiling of alphavirus inhibitors

  Weaver, S.

  3/1/15 → 2/15/16

  Project: Other project

• Antiviral profiling of alphavirus inhibitors

  Weaver, S.

  VenatoRx Pharmaceuticals, Inc.

  3/1/15 → 2/15/16

  Project: Other project

• Antiviral profiling of alphavirus inhibitors

  Aguilar, P.

  12/1/17 → 7/31/19

  Project: Other project

• Antiviral profiling of alphavirus inhibitors

  Aguilar, P.

  VenatoRx Pharmaceuticals, Inc.

  12/1/17 → 7/31/19

  Project: Other project

• Antivirals against Lassa (Sponsored Programs Contract)

  Paessler, S.

  11/1/18 → 10/31/19

  Project: Other project

• Antivirals against Lassa (Sponsored Programs Contract)

  Paessler, S.

  Shionogi & Co., Ltd.

  11/1/18 → 10/31/19

  Project: Other project

• Antiviral Testing of Inhibitors of SARS-CoV-2

  Shi, P.

  Aligos Therapeutics Inc

  12/1/20 → 6/30/21

  Project: Other project

• Antiviral Testing of Inhibitors of SARS-CoV-2

  Shi, P.

  12/1/20 → 6/30/21

  Project: Other project

• Antiviral therapies against re-emerging pathogens

  Paessler, S.

  Trek Therapeutics PBC

  2/1/15 → 12/31/16

  Project: Other project

• Antiviral therapies against re-emerging pathogens

  Paessler, S.

  2/1/15 → 12/31/16

  Project: Other project

• APA

  Keiser, P.

  4/1/16 → 3/31/17

  Project: Other project

• APA

  Keiser, P.

  4/1/16 → 3/31/17

  Project: Other project

• APEX Cooperative Multicenter Maternal-Fetal Medicine Unit

  Saade, G.

  4/1/09 → 3/31/21

  Project: Other project

• APEX Cooperative Multicenter Maternal-Fetal Medicine Unit

  Saade, G.

  4/1/09 → 3/31/21

  Project: Other project

• A Phase 1,Open Label, Single Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Dalbavancin in Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment for Bacterial Infections

  Aigbivbalu, L.

  11/13/13 → 11/12/15

  Project: Other project

• A Phase 1,Open Label, Single Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Dalbavancin in Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment for Bacterial Infections

  Aigbivbalu, L.

  DUKE UNIVERSITY

  11/13/13 → 11/12/15

  Project: Other project

• A Phase 1,Open Label, Single Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Dalbavancin in Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment for Bacterial Infections¿

  Aigbivbalu, L.

  11/13/13 → 11/12/15

  Project: Other project

• A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ORALLY ADMINISTERED NIRMATRELVIR/RITONAVIR IN PREGNANT WOMEN WITH MILD-TOMODERATE COVID-19

  Saade, G.

  Pfizer, Inc.

  5/26/22 → 5/25/27

  Project: Other project

• A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ORALLY ADMINISTERED NIRMATRELVIR/RITONAVIR IN PREGNANT WOMEN WITH MILD-TOMODERATE COVID-19

  Saade, G.

  1/1/00 → 1/1/00

  Project: Other project

• A Phase 1, Randomized, Single Dose, Blinded, Dose-Escalation Study to Assess Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator

  Rupp, R.

  6/19/20 → 6/18/23

  Project: Other project

• A Phase 1, Randomized, Single Dose, Blinded, Dose-Escalation Study to Assess Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator

  Rupp, R.

  Astellas Pharma Global Development Inc

  6/19/20 → 6/18/23

  Project: Other project

• A Phase 1, Randomized, Single Dose, Blinded, Dose-Escalation Study to Assess Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator

  Rupp, R.

  Astellas Pharma Global Development Inc

  6/19/20 → 6/18/23

  Project: Other project

• A PHASE 1, SINGLE-ASCENDING DOSE, MULTIPLE-ASCENDING DOSE, AND MULTI DOSE SAFETY, TOLERABILITY, PHARAMCOKINETICS, AND PHARACODYNAMICS STUDY OF SUBCUTANEOUSLY ADMINISTERED ALN-AS1 IN PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP)

  Anderson, K.

  Alnylam Pharmaceuticals, Inc

  1/22/16 → 1/21/19

  Project: Other project

• A PHASE 1, SINGLE-ASCENDING DOSE, MULTIPLE-ASCENDING DOSE, AND MULTI DOSE SAFETY, TOLERABILITY, PHARAMCOKINETICS, AND PHARACODYNAMICS STUDY OF SUBCUTANEOUSLY ADMINISTERED ALN-AS1 IN PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP)

  Anderson, K.

  1/22/16 → 1/21/19

  Project: Other project

• A PHASE 1, SINGLE-ASCENDING DOSE, MULTIPLE-ASCENDING DOSE, AND MULTI DOSE SAFETY, TOLERABILITY, PHARAMCOKINETICS, AND PHARACODYNAMICS STUDY OF SUBCUTANEOUSLY ADMINISTERED ALN-AS1 IN PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP)

  Anderson, K.

  1/22/16 → 1/21/19

  Project: Other project

• A Phase 1/2, First-Time-in Human (FTiH), randomized, observer-blind, placebo-controlled, dose escalation study to assess safety, reactogenicity and immunogenicity of a candidate cytomegalovirus (CMV) vaccine comprising recombinant protein and adjuvant wh

  Rupp, R.

  GlaxoSmithKline Pharmaceuticals

  1/1/00 → 1/1/00

  Project: Other project

• A Phase 1/2, First-Time-in Human (FTiH), randomized, observer-blind, placebo-controlled, dose escalation study to assess safety, reactogenicity and immunogenicity of a candidate cytomegalovirus (CMV) vaccine comprising recombinant protein and adjuvant wh

  Rupp, R.

  11/12/21 → 11/11/26

  Project: Other project

• A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose Finding Study To Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of SARS-CoV-2 RNA Vaccine Candidates against COVID 19 in Healthy Adults

  Rupp, R.

  Pfizer, Inc.

  6/19/20 → 6/18/24

  Project: Other project

• A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose Finding Study To Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of SARS-CoV-2 RNA Vaccine Candidates against COVID 19 in Healthy Adults

  Rupp, R.

  Pfizer, Inc.

  6/19/20 → 6/18/24

  Project: Other project

• A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose Finding Study To Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of SARS-CoV-2 RNA Vaccine Candidates against COVID 19 in Healthy Adults

  Rupp, R.

  6/19/20 → 6/18/24

  Project: Other project

• A Phase 1/2a Open-Label Dose-Ranging and Observer-Blind Placebo-Controlled, Safety and Immunogenicity Study of mRNA-1647 Cytomegalovirus Vaccine in Female and Male Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

  Rupp, R.

  Moderna Therapeutics Inc

  1/1/00 → 1/1/00

  Project: Other project

• A Phase 1/2a Open-Label Dose-Ranging and Observer-Blind Placebo-Controlled, Safety and Immunogenicity Study of mRNA-1647 Cytomegalovirus Vaccine in Female and Male Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

  Rupp, R.

  1/1/00 → 1/1/00

  Project: Other project

• A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) after Receipt of EUA Vaccines

  Rupp, R.

  7/14/21 → 11/30/22

  Project: Other project

• A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) after Receipt of EUA Vaccines

  Rupp, R.

  BAYLOR COLLEGE OF MEDICINE

  1/1/00 → 1/1/00

  Project: Other project

• A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, and

  Rupp, R.

  ModernaTX Inc

  2/12/20 → 2/11/25

  Project: Other project

• A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, and

  Rupp, R.

  2/12/20 → 2/11/25

  Project: Other project

• A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, and

  Rupp, R.

  2/12/20 → 2/11/25

  Project: Other project

• A Phase 2, Multicenter, Double-masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety, Efficacy, and Pharmacokinetics of the Fixed Combination of AGN-199201 and AGN-190584 in Patients with Presbyopia

  Merkley, K.

  9/21/16 → 9/20/18

  Project: Other project

• A Phase 2, Multicenter, Double-masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety, Efficacy, and Pharmacokinetics of the Fixed Combination of AGN-199201 and AGN-190584 in Patients with Presbyopia

  Merkley, K.

  Allergan

  9/21/16 → 9/20/18

  Project: Other project

• A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Three Different Potency Levels of V181 (Dengue Quadrivalent Vaccine rDENV30 live, attenuated in Healthy Adults

  Rupp, R.

  1/1/00 → 1/1/00

  Project: Other project

• A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Three Different Potency Levels of V181 (Dengue Quadrivalent Vaccine rDENV30 live, attenuated in Healthy Adults

  Rupp, R.

  Merck Sharp & Dohme Corporation

  1/1/00 → 1/1/00

  Project: Other project

• A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults with Inadequately Controlled Asthma on Inhaled Corticosteroids and at least one additional asthma control

  Calhoun, W.

  2/6/19 → 2/5/22

  Project: Other project

• A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults with Inadequately Controlled Asthma on Inhaled Corticosteroids and at least one additional asthma control

  Calhoun, W.

  AstraZeneca LP

  2/6/19 → 2/5/22

  Project: Other project